D-erythro-Sphingosine-13C2,d2
Product Specifications
UNSPSC Description
D-erythro-Sphingosine-13C2,d2 is a deuterated labeled D-erythro-Sphingosine[1]. D-erythro-Sphingosine (Erythrosphingosine) is a very potent activator of p32-kinase with an EC50 of 8 μM, and inhibits protein kinase C (PKC). D-erythro-Sphingosine (Erythrosphingosine) is also a PP2A activator[2][3][4][5].
Target Antigen
Endogenous Metabolite; Isotope-Labeled Compounds; Phosphatase; PKC
Type
Isotope-Labeled Compounds
Related Pathways
Epigenetics;Metabolic Enzyme/Protease;Others;TGF-beta/Smad
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Smiles
CCCCCCCCCCCCC/C=C/[C@@H](O)[13C@@H](N)[13C]([2H])([2H])O
Molecular Weight
303.49
References & Citations
[1]Cheng P, et al. Protein phosphatase 2A (PP2A) activation promotes axonal growth and recovery in the CNS. J Neurol Sci. 2015 Dec 15;359(1-2):48-56.|[2]Pushkareva MYu, et al. Regulation of sphingosine-activated protein kinases: selectivity of activation by sphingoid basesand inhibition by non-esterified fatty acids. Biochem J. 1993 Sep 15;294 ( Pt 3):699-703.|[3]Khan WA, et al. Protein kinase C and platelet inhibition by D-erythro-Sphingosine: comparison with N,N-dimethylsphingosine and commercial preparation. Biochem Biophys Res Commun. 1990 Oct 30;172(2):683-91.|[4]Pham VT, et al. A concise synthesis of a promising protein kinase C inhibitor: D-erythro-Sphingosine. Arch Pharm Res. 2007 Jan;30(1):22-7.|[5]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216.
Shipping Conditions
Room temperature
Clinical Information
No Development Reported
CAS Number
2692623-81-5
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items